Exhibit 99.1

 


Ruthigen Reports Fourth Quarter and Fiscal Year 2014 Financial Results

 

SANTA ROSA, Calif. — (June 30, 2014) —

Ruthigen, Inc. (NASDAQ: RTGN) today reported financial results for its fourth quarter and fiscal year ended March 31, 2014.

 

"We are poised to commence patient enrollment in the initial phase of our first human clinical trial using RUT58-60 in July 2014, and plan to complete our Phase 1/2 clinical trial in less than nine months,” said Hoji Alimi, Chairman, CEO and CSO of Ruthigen. "We believe that the completion of our recent initial public offering has provided Ruthigen with sufficient funding to complete our planned Phase 1/2 clinical trial and fund our operations for approximately 18 months.”

 

Mr. Alimi continued, “The key potential clinical and economic advantages of RUT58-60 versus the current standard of care stem from the broad-spectrum antimicrobial effectiveness of RUT58-60 against gram-negative and gram-positive bacteria with the potential to prevent the emergence of newly developed superbugs. If ultimately approved, we believe RUT58-60 will be the first prophylactic drug for use in all abdominal surgeries for prevention of infection without concerns regarding bacterial resistance or tolerability.”

 

Fiscal Fourth Quarter 2014 Financial Results

 

As of March 31, 2014, Ruthigen had cash of $15.6 million. Subsequently, the Company raised additional net proceeds of approximately $0.9 million in May 2014 when the underwriters in Ruthigen’s initial public offering completed a partial exercise of their over-allotment option.

 

For the three months ended March 31, 2014, Ruthigen reported a net loss of $1.0 million, or $0.46 per share, compared to a net loss of $0.5 million, or $0.23 per share, for the prior fiscal year.

 

Research and development expenses for the three months ended March 31, 2014 were $0.3 million compared to $0.2 million for the same period in fiscal 2013. The increase was primarily a result of the commencement of Ruthigen’s operations directly related to RUT58-60 in January 2013.

 

Selling, general and administrative expenses for the three months ended March 31, 2014 were $0.7 million, compared to $0.3 million for the same period in fiscal 2013. This increase was primarily a result of the commencement of Ruthigen’s independent operations in January 2013, when it was incorporated, executive and director bonuses, legal and accounting costs, and other consulting and professional fees.

 


The following information was filed by Pulmatrix, Inc. (PULM) on Monday, June 30, 2014 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Pulmatrix, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Pulmatrix, Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Log in with your credentials

or    

Forgot your details?

Create Account